{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T06:15:58Z","timestamp":1772000158435,"version":"3.50.1"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100005052","name":"Mission on Nano Science and Technology","doi-asserted-by":"publisher","award":["DST\/INSPIRE\/04\/2018\/003541"],"award-info":[{"award-number":["DST\/INSPIRE\/04\/2018\/003541"]}],"id":[{"id":"10.13039\/501100005052","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Microbiol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00284-023-03366-1","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T18:03:00Z","timestamp":1688666580000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Repurposing Polyether Ionophores as a New-Class of Anti-SARS-Cov-2 Agents as Adjunct Therapy"],"prefix":"10.1007","volume":"80","author":[{"given":"Keerthana","family":"Gurukkalot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1453-1139","authenticated-orcid":false,"given":"Vinoth","family":"Rajendran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,6]]},"reference":[{"key":"3366_CR1","unstructured":"Organization WHO (2022) COVID-19 weekly epidemiological update. Accessed 22 Feb 2022"},{"issue":"3","key":"3366_CR2","doi-asserted-by":"crossref","first-page":"pgac096","DOI":"10.1093\/pnasnexus\/pgac096","volume":"1","author":"S Mullin","year":"2022","unstructured":"Mullin S et al (2022) Modeling pandemic to endemic patterns of SARS-CoV-2 transmission using parameters estimated from animal model data. PANS Nexus 1(3):pgac096","journal-title":"PANS Nexus"},{"issue":"6516","key":"3366_CR3","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1126\/science.abe5960","volume":"370","author":"J Shaman","year":"2020","unstructured":"Shaman J, Galanti MJS (2020) Will SARS-CoV-2 become endemic? Science 370(6516):527\u2013529","journal-title":"Science"},{"key":"3366_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-022-00155-x","author":"AJN Katzourakis","year":"2022","unstructured":"Katzourakis AJN (2022) COVID-19: endemic doesn\u2019t mean harmless. Nature. https:\/\/doi.org\/10.1038\/d41586-022-00155-x","journal-title":"Nature"},{"issue":"12","key":"3366_CR5","doi-asserted-by":"crossref","first-page":"e0243882","DOI":"10.1371\/journal.pone.0243882","volume":"15","author":"LG Jacobs","year":"2020","unstructured":"Jacobs LG et al (2020) Persistence of symptoms and quality of life at 35 days after hospitalization for COVID-19 infection. PLOS One 15(12)","journal-title":"PLOS One"},{"issue":"10223","key":"3366_CR6","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","volume":"395","author":"N Chen","year":"2020","unstructured":"Chen N et al (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395(10223):507\u2013513","journal-title":"Lancet"},{"issue":"16","key":"3366_CR7","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1056\/NEJMc2201849","volume":"386","author":"J Yu","year":"2022","unstructured":"Yu J et al (2022) Neutralization of the SARS-CoV-2\u00a0Omicron BA.1 and BA.2 variants. New Engl J Med 386(16):1579\u20131580","journal-title":"New Engl J Med"},{"issue":"4","key":"3366_CR8","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3390\/jdb9040058","volume":"9","author":"R Perez-Gomez","year":"2021","unstructured":"Perez-Gomez R (2021) The development of SARS-CoV-2 variants: the gene makes the disease. J Dev Biol 9(4):58","journal-title":"J Dev Biol"},{"issue":"12","key":"3366_CR9","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41576-021-00408-x","volume":"22","author":"K Tao","year":"2021","unstructured":"Tao K et al (2021) The biological and clinical significance of emerging SARS-CoV-2 variants. Nat Rev Genet 22(12):757\u2013773","journal-title":"Nat Rev Genet"},{"issue":"3","key":"3366_CR10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","volume":"19","author":"P V\u2019kovski","year":"2021","unstructured":"V\u2019kovski P et al (2021) Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol 19(3):155\u2013170","journal-title":"Nat Rev Microbiol"},{"issue":"9","key":"3366_CR11","first-page":"3204","volume":"39","author":"AA Elfiky","year":"2021","unstructured":"Elfiky AA (2021) SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective. J Biomol Struct Dyn 39(9):3204\u20133212","journal-title":"J Biomol Struct Dyn"},{"issue":"5","key":"3366_CR12","doi-asserted-by":"crossref","first-page":"e1000054","DOI":"10.1371\/journal.ppat.1000054","volume":"4","author":"MJ van Hemert","year":"2008","unstructured":"van Hemert MJ et al (2008) SARS-coronavirus replication\/transcription complexes are membrane-protected and need a host factor for activity in vitro. PLoS Pathog 4(5):e1000054","journal-title":"PLoS Pathog"},{"issue":"1","key":"3366_CR13","first-page":"3","volume":"42","author":"YA Malik","year":"2020","unstructured":"Malik YA (2020) Properties of coronavirus and SARS-CoV-2. Malays J Pathol 42(1):3\u201311","journal-title":"Malays J Pathol"},{"issue":"4","key":"3366_CR14","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3390\/cells10040821","volume":"10","author":"R Yadav","year":"2021","unstructured":"Yadav R et al (2021) Role of structural and non-structural proteins and therapeutic targets of SARS-CoV-2 for COVID-19. Cells 10(4):821","journal-title":"Cells"},{"key":"3366_CR15","doi-asserted-by":"crossref","first-page":"100719","DOI":"10.1016\/j.drup.2020.100719","volume":"53","author":"S Dro\u017cd\u017cal","year":"2020","unstructured":"Dro\u017cd\u017cal S et al (2020) FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. Drug Resist Updat 53","journal-title":"Drug Resist Updates"},{"issue":"6","key":"3366_CR16","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s43440-020-00155-6","volume":"72","author":"TU Singh","year":"2020","unstructured":"Singh TU et al (2020) Drug repurposing approach to fight COVID-19. Pharmacol Rep 72(6):1479\u20131508","journal-title":"Pharmacol Rep"},{"issue":"1","key":"3366_CR17","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","volume":"6","author":"J Liu","year":"2020","unstructured":"Liu J et al (2020) Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 6(1):16","journal-title":"Cell Discov"},{"issue":"3","key":"3366_CR18","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang M et al (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30(3):269\u2013271","journal-title":"Cell Res"},{"issue":"7826","key":"3366_CR19","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s41586-020-2575-3","volume":"585","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M et al (2020) Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2. Nature 585(7826):588\u2013590","journal-title":"Nature"},{"issue":"25","key":"3366_CR20","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2012410","volume":"382","author":"J Geleris","year":"2020","unstructured":"Geleris J et al (2020) Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med 382(25):2411\u20132418","journal-title":"N Engl J Med"},{"issue":"1","key":"3366_CR21","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.medj.2020.06.001","volume":"1","author":"J Magagnoli","year":"2020","unstructured":"Magagnoli J et al (2020) Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. Med 1(1):114","journal-title":"Med"},{"issue":"3","key":"3366_CR22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/jmcb\/mjab016","volume":"13","author":"D Altulea","year":"2021","unstructured":"Altulea D et al (2021) What makes (hydroxy) chloroquine ineffective against COVID-19: insights from cell biology. J Mol Cell Biol 13(3):175\u2013184","journal-title":"J Mol Cell Biol"},{"key":"3366_CR23","doi-asserted-by":"crossref","first-page":"791","DOI":"10.3389\/fphar.2020.00791","volume":"11","author":"M Sisay","year":"2020","unstructured":"Sisay M (2020) Available evidence and ongoing clinical trials of remdesivir: could it be a promising therapeutic option for COVID-19? Front Pharmacol 11:791","journal-title":"Front Pharmacol"},{"issue":"8","key":"3366_CR24","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1021\/cr940394a","volume":"97","author":"E Bakker","year":"1997","unstructured":"Bakker E, B\u00fchlmann P, Pretsch E (1997) Carrier-based ion-selective electrodes and bulk optodes. 1. general characteristics. Chem Rev 97(8):3083\u20133132","journal-title":"Chem Rev"},{"key":"3366_CR25","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0065-2164(08)70163-1","volume":"22","author":"JJ Westley","year":"1977","unstructured":"Westley JJ (1977) Polyether antibiotics: versatile carboxylic acid ionophores produced by Streptomyces. Adv Appl Microbiol 22:177\u2013223","journal-title":"Adv Appl Microbiol"},{"issue":"22","key":"3366_CR26","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.2174\/1568026619666181129141151","volume":"18","author":"V Rajendran","year":"2018","unstructured":"Rajendran V et al (2018) Chemotherapeutic potential of monensin as an anti-microbial agent. Curr Top Med Chem 18(22):1976\u20131986","journal-title":"Curr Top Med Chem"},{"issue":"1","key":"3366_CR27","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1146\/annurev.bi.45.070176.002441","volume":"45","author":"BC Pressman","year":"1976","unstructured":"Pressman BC (1976) Biological\napplications of ionophores. Annu Rev Biochem 45(1):501\u2013530","journal-title":"Annu Rev Biochem"},{"issue":"9","key":"3366_CR28","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.3382\/ps.2010-00931","volume":"89","author":"H Chapman","year":"2010","unstructured":"Chapman H, Jeffers T, Williams R (2010) Forty years of monensin for the control of coccidiosis in poultry. Poult\nSci 89(9):1788\u20131801","journal-title":"Poult Sci"},{"key":"3366_CR29","doi-asserted-by":"crossref","first-page":"113038","DOI":"10.1016\/j.phytochem.2021.113038","volume":"195","author":"E Gezer","year":"2022","unstructured":"Gezer E et al (2022) Undescribed polyether ionophores from Streptomyces cacaoi and their antibacterial and antiproliferative activities. Phytochemistry 195","journal-title":"Phytochemistry"},{"issue":"2","key":"3366_CR30","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1039\/np9951200165","volume":"12","author":"C Dutton","year":"1995","unstructured":"Dutton C, Banks B, Cooper C (1995) Polyether ionophores. Nat Prod Rep 12(2):165\u2013181","journal-title":"Nat Prod Rep"},{"key":"3366_CR31","doi-asserted-by":"publisher","DOI":"10.1101\/2020.10.27.354563","author":"J-Q Li","year":"2020","unstructured":"Li J-Q et al (2020) Aglycone polyether ionophores as broad-spectrum agents inhibit multiple enveloped viruses including SARS-CoV-2 in vitro and successfully cure JEV infected mice. BioRxiv. https:\/\/doi.org\/10.1101\/2020.10.27.354563","journal-title":"BioRxiv"},{"issue":"7","key":"3366_CR32","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1007\/s00436-019-06343-5","volume":"118","author":"S Noack","year":"2019","unstructured":"Noack S, Chapman HD, Selzer PM (2019) Anticoccidial drugs of the livestock industry. Parasitol Res 118(7):2009\u20132026","journal-title":"Parasitol Res"},{"issue":"1","key":"3366_CR33","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41557-020-00601-1","volume":"13","author":"S Lin","year":"2021","unstructured":"Lin S et al (2021) Expanding the antibacterial selectivity of polyether ionophore antibiotics through diversity-focused semisynthesis. Nat Chem 13(1):47\u201355","journal-title":"Nat Chem"},{"key":"3366_CR34","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejmech.2019.01.035","volume":"166","author":"M Antoszczak","year":"2019","unstructured":"Antoszczak M, Steverding D, Huczy\u0144ski A (2019) Anti-parasitic activity of polyether ionophores. Eur\nJ Med Chem 166:32\u201347","journal-title":"Eur J Med Chem"},{"issue":"5","key":"3366_CR35","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2174\/1871520615666150101130209","volume":"15","author":"M Antoszczak","year":"2015","unstructured":"Antoszczak M, Huczy\u0144ski A (2015) Anticancer activity of polyether ionophore-salinomycin. Anticancer\nAgents Med Chem 15(5):575\u2013591","journal-title":"Anticancer Agents Med Chem"},{"issue":"10","key":"3366_CR36","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3390\/cancers10100360","volume":"10","author":"V Kaushik","year":"2018","unstructured":"Kaushik V et al (2018) Ionophores: potential use as anticancer drugs and chemosensitizers. Cancers 10(10):360","journal-title":"Cancers"},{"issue":"11","key":"3366_CR37","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1634\/theoncologist.2016-0159","volume":"21","author":"M Boesch","year":"2016","unstructured":"Boesch M, Sopper S, Wolf D (2016) Ionophore antibiot as cancer stem cell-selective drugs: open questions. Oncologist 21(11):1291\u20131293","journal-title":"Oncologist"},{"key":"3366_CR38","unstructured":"Fong C (2021) Ionophores and inhibition of SARS-CoV-2 ion channels. Eigenenergy Adelaide. South Australia, Australia. hal-03347139v2"},{"key":"3366_CR39","doi-asserted-by":"crossref","first-page":"104988","DOI":"10.1016\/j.antiviral.2020.104988","volume":"185","author":"EB Svenningsen","year":"2021","unstructured":"Svenningsen EB et al (2021) Ionophore antibiotic X-206 is a potent inhibitor of SARS-CoV-2 infection in vitro. AntiviralRes 185","journal-title":"Antiviral Res"},{"issue":"1","key":"3366_CR40","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0168-6445(03)00019-6","volume":"27","author":"JB Russell","year":"2003","unstructured":"Russell JB, Houlihan AJ (2003) Ionophore\nresistance of ruminal bacteria and its potential impact on human health. FEMS\nMicrobiol Rev 27(1):65\u201374","journal-title":"FEMS Microbiol Rev"},{"issue":"1\u20136","key":"3366_CR41","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1699-0463.1998.tb01391.x","volume":"106","author":"FM Aarestrup","year":"1998","unstructured":"Aarestrup FM et al (1998) Surveillance of antimicrobial resistance in bacteria isolated from food animals to antimicrobial growth promoters and related therapeutic agents in Denmark. APMIS 106(1\u20136):606\u2013622","journal-title":"APMIS"},{"issue":"2","key":"3366_CR42","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.3892\/mmr.2015.3633","volume":"12","author":"KY Kim","year":"2015","unstructured":"Kim KY et al (2015) Salinomycin enhances doxorubicin-induced cytotoxicity in multidrug resistant MCF-7\/MDR human breast cancer cells\u00a0via decreased efflux of doxorubicin. Mol\nMed Rep 12(2):1898\u20131904","journal-title":"Mol Med Rep"},{"issue":"3","key":"3366_CR43","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.3892\/or.2015.4509","volume":"35","author":"A Hermawan","year":"2016","unstructured":"Hermawan A, Wagner E, Roidl A (2016) Consecutive salinomycin treatment reduces doxorubicin resistance of breast tumor cells by diminishing drug efflux pump expression and activity. Oncol\nRep 35(3):1732\u20131740","journal-title":"Oncol Rep"},{"issue":"23","key":"3366_CR44","doi-asserted-by":"crossref","first-page":"7002","DOI":"10.1016\/j.bmcl.2012.09.046","volume":"22","author":"A Huczynski","year":"2012","unstructured":"Huczynski A (2012) Polyether ionophores-promising bioactive molecules for cancer therapy. Bioorg Med Chem Lett 22(23):7002\u20137010","journal-title":"Bioorg Med Chem Lett"},{"issue":"4","key":"3366_CR45","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1039\/C8RA07641C","volume":"9","author":"MB Patel","year":"2019","unstructured":"Patel MB et al (2019) Synthetic ionophores as non-resistant antibiotic adjuvants. RSC Adv 9(4):2217\u20132230","journal-title":"RSC Adv"},{"issue":"5","key":"3366_CR46","doi-asserted-by":"crossref","first-page":"e0217602","DOI":"10.1371\/journal.pone.0217602","volume":"14","author":"J Magallon","year":"2019","unstructured":"Magallon J et al (2019) Restoration of susceptibility to amikacin by 8-hydroxyquinoline analogs complexed to zinc. PLoS One 14(5):e0217602","journal-title":"PLoS One"},{"key":"3366_CR47","doi-asserted-by":"crossref","first-page":"100089","DOI":"10.1016\/j.medidd.2021.100089","volume":"10","author":"N Goel","year":"2021","unstructured":"Goel N et al (2021) New threatening of SARS-CoV-2 coinfection and strategies to fight the current pandemic. Med Drug Discov 10:100089","journal-title":"Med Drug Discov"},{"issue":"11","key":"3366_CR48","doi-asserted-by":"crossref","first-page":"e0009921","DOI":"10.1371\/journal.pntd.0009921","volume":"15","author":"JM Aranjani","year":"2021","unstructured":"Aranjani JM et al (2021) COVID-19\u2013associated mucormycosis: evidence-based critical review of an emerging infection burden during the pandemic\u2019s second wave in India. PLoS Negl Top Dis 15(11):e0009921","journal-title":"PLoS Negl Top Dis"},{"issue":"7","key":"3366_CR49","doi-asserted-by":"crossref","first-page":"e543","DOI":"10.1016\/S2666-5247(21)00237-8","volume":"3","author":"M Hoenigl","year":"2022","unstructured":"Hoenigl M et al (2022) The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe 3(7):e543\u2013e552","journal-title":"Lancet Microbe"},{"issue":"1","key":"3366_CR50","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41479-021-00083-w","volume":"13","author":"C Feldman","year":"2021","unstructured":"Feldman C, Anderson R (2021) The role of co-infections and secondary infections in patients with COVID-19. Pneumonia (Nathan) 13(1):5","journal-title":"Pneumonia (Nathan)"},{"issue":"4","key":"3366_CR51","doi-asserted-by":"crossref","first-page":"e0249668","DOI":"10.1371\/journal.pone.0249668","volume":"16","author":"S He","year":"2021","unstructured":"He S et al (2021) Clinical characteristics of COVID-19 patients with clinically diagnosed bacterial co-infection: a multi-center study. PLoS One 16(4):e0249668","journal-title":"PLoS One"},{"issue":"10","key":"3366_CR52","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1002\/iub.2356","volume":"72","author":"R Mirzaei","year":"2020","unstructured":"Mirzaei R et al (2020) Bacterial co-infections with SARS-CoV-2. IUBMB Life 72(10):2097\u20132111","journal-title":"IUBMB Life"},{"issue":"2","key":"3366_CR53","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1517\/17460440802661443","volume":"4","author":"DA Kevin Ii","year":"2009","unstructured":"Kevin Ii DA, Meujo DA, Haman MT (2009) Polyether ionophores: broad-spectrum and promising biologically active molecules for the control of drug-resistant bacteria and parasites. Expert Opin Drug Discov 4(2):109\u2013146","journal-title":"Expert Opin Drug Discov"},{"issue":"4","key":"3366_CR54","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/0092-8674(83)90286-6","volume":"32","author":"AM Tartakoff","year":"1983","unstructured":"Tartakoff AM (1983) Perturbation of vesicular traffic with the carboxylic ionophore monensin. Cell 32(4):1026\u20131028","journal-title":"Cell"},{"issue":"3","key":"3366_CR55","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1083\/jcb.79.3.694","volume":"79","author":"A Tartakoff","year":"1978","unstructured":"Tartakoff A, Vassalli P, D\u00e9traz M (1978) Comparative\nstudies of intracellular transport of secretory proteins. J\nCell Biol 79(3):694\u2013707","journal-title":"J Cell Biol"},{"key":"3366_CR56","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1083\/jcb.96.3.835","volume":"96","author":"G Griffiths","year":"1983","unstructured":"Griffiths G, Quinn P, Warren G (1983) Monensin inhibits the transport of viral membrane proteins from medial to trans golgi cisternae in baby hamster kidney cells infected with Semliki Forest virus. J Cell Biol 96:835\u2013850","journal-title":"J Cell Biol"},{"key":"3366_CR57","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0076-6879(83)98138-7","volume":"98","author":"AM Tartakoff","year":"1983","unstructured":"Tartakoff AM (1983) [5] perturbation of the structure and function of the golgi complex by monovalent carboxylic ionophores. Methods Enzymol 98:47\u201359","journal-title":"Methods Enzymol"},{"issue":"2","key":"3366_CR58","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0168-1702(84)90070-4","volume":"1","author":"FV Alonso-Caplen","year":"1984","unstructured":"Alonso-Caplen FV et al (1984) Replication and morphogenesis of avian coronavirus in Vero cells and their inhibition by monensin. Virus Resp 1(2):153\u2013167","journal-title":"Virus Resp"},{"issue":"12","key":"3366_CR59","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/j.1460-2075.1982.tb01346.x","volume":"1","author":"H Niemann","year":"1982","unstructured":"Niemann H et al (1982) Post-translational glycosylation of coronavirus glycoprotein E1: inhibition by monensin. EMBO J 1(12):1499\u20131504","journal-title":"EMBO J"},{"issue":"3","key":"3366_CR60","doi-asserted-by":"crossref","first-page":"e1009439","DOI":"10.1371\/journal.ppat.1009439","volume":"17","author":"X Ju","year":"2021","unstructured":"Ju X et al (2021) A novel cell culture system modeling the SARS-CoV-2 life cycle. PLoS Pathog 17(3):e1009439","journal-title":"PLoS Pathog"},{"key":"3366_CR61","doi-asserted-by":"crossref","first-page":"586572","DOI":"10.3389\/fimmu.2020.586572","volume":"11","author":"X Xiao","year":"2020","unstructured":"Xiao X et al (2020) Identification of potent and safe antiviral therapeutic candidates against SARS-CoV-2. Front Immunol 11:586572","journal-title":"Front Immunol"},{"issue":"4","key":"3366_CR62","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/cbdd.13812","volume":"97","author":"AK Verma","year":"2021","unstructured":"Verma AK, Aggarwal R (2021) Repurposing potential of FDA-approved and investigational drugs for COVID-19 targeting SARS-CoV-2 spike and main protease and validation by machine learning algorithm. Chem Biol Drug Des 97(4):836\u2013853","journal-title":"Chem Biol Drug Des"},{"issue":"7861","key":"3366_CR63","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41586-021-03491-6","volume":"594","author":"L Braga","year":"2021","unstructured":"Braga L et al (2021) Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia. Nature 594(7861):88\u201393","journal-title":"Nature"},{"issue":"6","key":"3366_CR64","doi-asserted-by":"crossref","first-page":"bbab249","DOI":"10.1093\/bib\/bbab249","volume":"22","author":"J Xing","year":"2021","unstructured":"Xing J et al (2021) Published anti-SARS-CoV-2 in vitro hits share common mechanisms of action that synergize with antivirals. Brief Bioinform 22(6):bbab249","journal-title":"Brief Bioinform"},{"issue":"12","key":"3366_CR65","doi-asserted-by":"crossref","first-page":"e00023","DOI":"10.1128\/JVI.00023-19","volume":"93","author":"L Shen","year":"2019","unstructured":"Shen L et al (2019) High-throughput screening and identification of potent broad-spectrum inhibitors of coronaviruses. J Virol 93(12):e00023\u2013e00019","journal-title":"J Virol"},{"issue":"11","key":"3366_CR66","doi-asserted-by":"crossref","first-page":"814","DOI":"10.7164\/antibiotics.27.814","volume":"27","author":"Y Miyazaki","year":"1974","unstructured":"Miyazaki Y et al (1974) Salinomycin, a new polyether antibiotic. J Antibiot 27(11):814\u2013821","journal-title":"J Antibiot"},{"issue":"7","key":"3366_CR67","doi-asserted-by":"crossref","first-page":"e00819","DOI":"10.1128\/AAC.00819-20","volume":"64","author":"S Jeon","year":"2020","unstructured":"Jeon S et al (2020) Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. Antimicrob Agents Chemother 64(7):e00819\u2013e00820","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"3366_CR68","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.bj.2020.05.003","volume":"43","author":"C-W Yang","year":"2020","unstructured":"Yang C-W et al (2020) Repurposing old drugs as antiviral agents for coronaviruses. Biomed J 43(4):368\u2013374","journal-title":"Biomed J"},{"issue":"1","key":"3366_CR69","doi-asserted-by":"crossref","first-page":"108959","DOI":"10.1016\/j.celrep.2021.108959","volume":"35","author":"M Dittmar","year":"2021","unstructured":"Dittmar M et al (2021) Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2. Cell Rep 35(1):108959","journal-title":"Cell Rep"},{"key":"3366_CR70","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-021-2031-7","author":"H Peng","year":"2021","unstructured":"Peng H et al (2021) Discovery of potential anti-SARS-CoV-2 drugs based on large-scale screening in vitro and effect evaluation in vivo. Sci China Life Sci. https:\/\/doi.org\/10.1007\/s11427-021-2031-7","journal-title":"Sci China Life Sci"},{"issue":"7852","key":"3366_CR71","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41586-020-2895-3","volume":"592","author":"JA Plante","year":"2021","unstructured":"Plante JA et al (2021) Spike mutation D614G alters SARS-CoV-2 fitness. Nature 592(7852):116\u2013121","journal-title":"Nature"},{"key":"3366_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.bj.2020.05.001","author":"Y Ke","year":"2020","unstructured":"Ke Y et al (2020) Artificial intelligence approach fighting COVID-19 with repurposing drugs. Biomed J. https:\/\/doi.org\/10.1016\/j.bj.2020.05.001","journal-title":"Biomed J"},{"key":"3366_CR73","doi-asserted-by":"crossref","first-page":"109858","DOI":"10.1016\/j.mehy.2020.109858","volume":"143","author":"SKS Pindiprolu","year":"2020","unstructured":"Pindiprolu SKS et al (2020) Pulmonary delivery of nanostructured lipid carriers for effective repurposing of salinomycin as an antiviral agent. Med Hypotheses 143:109858","journal-title":"Med Hypotheses"},{"issue":"12","key":"3366_CR74","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1136\/emj.2004.020883","volume":"22","author":"N Sharma","year":"2005","unstructured":"Sharma N et al (2005) Toxicity\nof maduramicin. Emerg Med J 22(12):880\u2013882","journal-title":"Emerg Med J"},{"issue":"6","key":"3366_CR75","doi-asserted-by":"crossref","first-page":"727","DOI":"10.7164\/antibiotics.43.727","volume":"43","author":"JP Dirlam","year":"1990","unstructured":"Dirlam JP, Presseau-Linabury L, Koss DA (1990) The structure of CP-80, 219, a new polyether antibiotic related to dianemycin. J Antibiot 43(6):727\u2013730","journal-title":"J Antibiot"},{"key":"3366_CR76","doi-asserted-by":"publisher","unstructured":"Antoszczak M et al (2014) Structure and biological activity of polyether ionophores and their semisynthetic derivatives.107\u2013170. https:\/\/doi.org\/10.1002\/9783527684403.CH6","DOI":"10.1002\/9783527684403.CH6"},{"issue":"6","key":"3366_CR77","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00203-011-0768-8","volume":"194","author":"Q Yu","year":"2012","unstructured":"Yu Q et al (2012) The biosynthesis of the polyether antibiotic nanchangmycin is controlled by two pathway-specific transcriptional activators. Arch Microbiol 194(6):415\u2013426","journal-title":"Arch Microbiol"},{"issue":"6","key":"3366_CR78","doi-asserted-by":"crossref","first-page":"e1009662","DOI":"10.1371\/journal.ppat.1009662","volume":"17","author":"N Sarute","year":"2021","unstructured":"Sarute N et al (2021) Signal-regulatory protein alpha is an anti-viral entry factor targeting viruses using endocytic pathways. PLoS Pathog 17(6):e1009662","journal-title":"PLoS Pathog"},{"key":"3366_CR79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/2666958702101010038","volume":"1","author":"S Rana","year":"2021","unstructured":"Rana S et al (2021) Identification of naturally occurring antiviral molecules for SARS-CoV-2 mitigation. Open COVID J 1:1","journal-title":"Open COVID J"},{"key":"3366_CR80","doi-asserted-by":"publisher","DOI":"10.1101\/2022.04.20.440626","author":"JJ Patten","year":"2022","unstructured":"Patten JJ et al (2022) Identification of druggable host targets needed for SARS-CoV-2 infection by combined pharmacological evaluation and cellular network directed prioritization both in vitro and in vivo. BioRxiv. https:\/\/doi.org\/10.1101\/2022.04.20.440626","journal-title":"BioRxiv"},{"issue":"1","key":"3366_CR81","doi-asserted-by":"crossref","first-page":"3","DOI":"10.33073\/pjm-2010-001","volume":"59","author":"MA Krote\u0144","year":"2010","unstructured":"Krote\u0144 MA, Bartoszewicz M, \u015awi\u0119cicka I (2010) Cereulide and valinomycin, two important natural dodecadepsipeptides with ionophoretic activities. PolJ Microbiol 59(1):3","journal-title":"Pol J Microbiol"},{"issue":"3","key":"3366_CR82","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1504\/IJCBDD.2016.078284","volume":"9","author":"C Fong","year":"2016","unstructured":"Fong C, Design D (2016) Physiology of ionophore transport of potassium and sodium ions across cell membranes: Valinomycin and 18-Crown-6 Ether. Int J Comput Biol Drug Des 9(3):228\u2013246","journal-title":"Int J Comput Biol Drug Des"},{"issue":"27","key":"3366_CR83","doi-asserted-by":"crossref","first-page":"10012","DOI":"10.1073\/pnas.0403596101","volume":"101","author":"C-Y Wu","year":"2004","unstructured":"Wu C-Y et al (2004) Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc\nNatl Acad Sci USA 101(27):10012\u201310017","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"3366_CR84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-24007-w","volume":"12","author":"NC Gassen","year":"2021","unstructured":"Gassen NC et al (2021) SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers host-targeting antivirals. Nat Commun 12(1):1\u201315","journal-title":"Nat Commun"},{"issue":"2","key":"3366_CR85","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s12011-020-02194-9","volume":"199","author":"MT Rahman","year":"2021","unstructured":"Rahman MT, Idid SZ (2021) Can Zn be a critical element in COVID-19 treatment? Biol Trace Elem Res 199(2):550\u2013558","journal-title":"Biol Trace Elem Res"},{"issue":"2","key":"3366_CR86","first-page":"144","volume":"18","author":"N Roohani","year":"2013","unstructured":"Roohani N et al (2013) Zinc and its importance for human health: an integrative review. J Res Med Sci 18(2):144\u2013157","journal-title":"J Res Med Sci"},{"key":"3366_CR87","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01712","author":"I Wessels","year":"2020","unstructured":"Wessels I, Rolles B, Rink L (2020) The potential impact of zinc supplementation on COVID-19 pathogenesis. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2020.01712","journal-title":"Front Immunol"},{"key":"3366_CR88","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3390\/nu13020562","volume":"13","author":"M Vogel-Gonz\u00e1lez","year":"2021","unstructured":"Vogel-Gonz\u00e1lez M, Tall\u00f3-Parra M, Herrera-Fern\u00e1ndez V, P\u00e9rez-Vilar\u00f3 G, Chill\u00f3n M, Nogu\u00e9s X, G\u00f3mez-Zorrilla S, L\u00f3pez-Montesinos I, Arnau-Barr\u00e9s I, Sorli-Red\u00f3 M (2021) Lowzinc levels at admission associates with poor clinical outcomes in SARS-CoV-2infection. Nutrients 13:562","journal-title":"Nutrients"},{"issue":"5","key":"3366_CR89","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.jmii.2021.01.012","volume":"54","author":"G Dubourg","year":"2021","unstructured":"Dubourg G et al (2021) Low blood zinc concentrations in patients with poor clinical outcome during SARS-CoV-2 infection: is there a need to supplement with zinc COVID-19 patients? Microbiol Immunol Infect 54(5):997\u20131000","journal-title":"Microbiol Immunol Infect"},{"key":"3366_CR90","doi-asserted-by":"crossref","first-page":"109815","DOI":"10.1016\/j.mehy.2020.109815","volume":"142","author":"R Derwand","year":"2020","unstructured":"Derwand R, Scholz M (2020) Does zinc supplementation enhance the clinical efficacy of chloroquine\/hydroxychloroquine to win today\u2019s battle against COVID-19? Med Hypotheses 142:109815","journal-title":"Med Hypotheses"},{"key":"3366_CR91","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26989","author":"V Cingolani","year":"2021","unstructured":"Cingolani V (2021) Hypothesis of zinc ascorbate as best zinc ionophore for raising antiviral resistance against Covid-19. J Med Virol. https:\/\/doi.org\/10.1002\/jmv.26989","journal-title":"J Med Virol"},{"issue":"78","key":"3366_CR92","doi-asserted-by":"crossref","first-page":"10083","DOI":"10.1039\/D1CC03563K","volume":"57","author":"W Ali\u00e1Khan","year":"2021","unstructured":"Ali\u00e1Khan W et al (2021) Zinc 2+ ion inhibits SARS-CoV-2 main protease and viral replication in vitro. Chem Commun (Camb) 57(78):10083\u201310086","journal-title":"Chem Commun (Camb)"},{"key":"3366_CR93","doi-asserted-by":"crossref","first-page":"111777","DOI":"10.1016\/j.jinorgbio.2022.111777","volume":"231","author":"X Tao","year":"2022","unstructured":"Tao X et al (2022) Inhibition of SARS-CoV-2 replication by zinc gluconate in combination with hinokitiol. J Inorg Biochem 231:111777","journal-title":"J Inorg Biochem"},{"issue":"11","key":"3366_CR94","doi-asserted-by":"crossref","first-page":"e1001176","DOI":"10.1371\/journal.ppat.1001176","volume":"6","author":"AJ Te Velthuis","year":"2010","unstructured":"Te Velthuis AJ et al (2010) Zn2+ inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. PLoS Pathog 6(11):e1001176","journal-title":"PLoS Pathog"},{"issue":"1","key":"3366_CR95","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1080\/14756366.2022.2108417","volume":"37","author":"J Kladnik","year":"2022","unstructured":"Kladnik J et al (2022) Zinc pyrithione is a potent inhibitor of PLPro and cathepsin L enzymes with ex vivo inhibition of SARS-CoV-2 entry and replication. J Enzyme Inhib Med Chem 37(1):2158\u20132168","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"10","key":"3366_CR96","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1099\/jmm.0.001250","volume":"69","author":"PM Carlucci","year":"2020","unstructured":"Carlucci PM et al (2020) Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients. J Med Microbiol 69(10):1228\u20131234","journal-title":"J Med Microbiol"},{"issue":"1","key":"3366_CR97","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1042\/BJ20081421","volume":"417","author":"H Yu","year":"2009","unstructured":"Yu H et al (2009) Clioquinol targets zinc to lysosomes\u00a0in\nhuman cancer cells. Biochem\nJ 417(1):133\u2013139","journal-title":"Biochem J"},{"key":"3366_CR98","doi-asserted-by":"crossref","first-page":"109706","DOI":"10.1016\/j.cellsig.2020.109706","volume":"73","author":"X Chen","year":"2020","unstructured":"Chen X, Geiger JD (2020) Janus sword actions of chloroquine and hydroxychloroquine against COVID-19. Cell Signal 73:109706","journal-title":"Cell Signal"},{"issue":"10","key":"3366_CR99","doi-asserted-by":"crossref","first-page":"e109180","DOI":"10.1371\/journal.pone.0109180","volume":"9","author":"J Xue","year":"2014","unstructured":"Xue J et al (2014) Chloroquine is a zinc ionophore. PLoS\nOne 9(10):e109180","journal-title":"PLoS One"},{"issue":"3","key":"3366_CR100","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2174\/187152607782110004","volume":"7","author":"CC Garc\u00eda","year":"2007","unstructured":"Garc\u00eda CC, Damonte EB (2007) Zn finger containing proteins as targets for the control of viral infections. Infect Disord Drug Targets 7(3):204\u2013212","journal-title":"Infect Disord Drug Targets"},{"issue":"7","key":"3366_CR101","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.3390\/ijms23073711","volume":"23","author":"S Esposito","year":"2022","unstructured":"Esposito S et al (2022) Host and viral zinc-finger proteins in COVID-19. Int J Mol Sci 23(7):3711","journal-title":"Int J Mol Sci"},{"issue":"7","key":"3366_CR102","doi-asserted-by":"crossref","first-page":"e0253364","DOI":"10.1371\/journal.pone.0253364","volume":"16","author":"LA Armstrong","year":"2021","unstructured":"Armstrong LA et al (2021) Biochemical characterization of protease activity of Nsp3 from SARS-CoV-2 and its inhibition by nanobodies. PLoS One 16(7):e0253364","journal-title":"PLoS One"},{"issue":"36","key":"3366_CR103","doi-asserted-by":"crossref","first-page":"9904","DOI":"10.1039\/D0SC02646H","volume":"11","author":"K Sargsyan","year":"2020","unstructured":"Sargsyan K et al (2020) Multi-targeting of functional cysteines in multiple conserved SARS-CoV-2 domains by clinically safe Zn-ejectors. Chem Sci 11(36):9904\u20139909","journal-title":"Chem Sci"},{"issue":"21","key":"3366_CR104","doi-asserted-by":"crossref","first-page":"4887","DOI":"10.1111\/bph.15199","volume":"177","author":"U Doboszewska","year":"2020","unstructured":"Doboszewska U et al (2020) Targeting zinc metalloenzymes in coronavirus disease 2019. BrJ pharmacol 177(21):4887\u20134898","journal-title":"BrJ pharmacol"},{"issue":"30","key":"3366_CR105","doi-asserted-by":"crossref","first-page":"9436","DOI":"10.1073\/pnas.1508686112","volume":"112","author":"Y Ma","year":"2015","unstructured":"Ma Y et al (2015) Structural basis and functional analysis of the SARS coronavirus nsp14\u2013nsp10 complex. Proc Natl Acad Sci USA 112(30):9436\u20139441","journal-title":"Proc Natl Acad Sci USA"},{"key":"3366_CR106","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.antiviral.2017.12.015","volume":"150","author":"M-H Lin","year":"2018","unstructured":"Lin M-H et al (2018) Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes. Antiviral Res 150:155\u2013163","journal-title":"Antiviral Res"},{"issue":"6","key":"3366_CR107","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3390\/v12060642","volume":"12","author":"A Ianevski","year":"2020","unstructured":"Ianevski A et al (2020) Potential antiviral options against SARS-CoV-2 infection. Viruses 12(6):642","journal-title":"Viruses"},{"issue":"3","key":"3366_CR108","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3390\/ph15030377","volume":"15","author":"T Kreiser","year":"2022","unstructured":"Kreiser T et al (2022) Inhibition of respiratory RNA viruses by a composition of ionophoric polyphenols with metal ions. Pharmaceuticals\u00a0(Basel) 15(3):377","journal-title":"Pharmaceuticals\u00a0(Basel)"},{"issue":"32","key":"3366_CR109","doi-asserted-by":"crossref","first-page":"8085","DOI":"10.1021\/jf5014633","volume":"62","author":"H Dabbagh-Bazarbachi","year":"2014","unstructured":"Dabbagh-Bazarbachi H et al (2014) Zinc ionophore activity of quercetin and epigallocatechin-gallate: from Hepa 1\u20136 cells to a liposome model. J Agric Food Chem 62(32):8085\u20138093","journal-title":"J Agric Food Chem"},{"issue":"9","key":"3366_CR110","doi-asserted-by":"crossref","first-page":"5135","DOI":"10.1128\/AAC.04332-14","volume":"59","author":"S D\u2019Alessandro","year":"2015","unstructured":"D\u2019Alessandro S et al (2015) Salinomycin and other ionophores as a new class of antimalarial drugs with transmission-blocking activity. Antimicrob Agents Chemother 59(9):5135\u20135144","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"3366_CR111","first-page":"1","volume":"22","author":"S Yao","year":"2021","unstructured":"Yao S et al (2021) Monensin suppresses cell proliferation and invasion in ovarian cancer by enhancing MEK1 SUMOylation. ExpTher Med 22(6):1\u201310","journal-title":"Exp Ther Med"},{"issue":"4","key":"3366_CR112","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1158\/1535-7163.MCT-13-0625","volume":"13","author":"L Tumova","year":"2014","unstructured":"Tumova L et al (2014) Monensin Inhibits Canonical Wnt Signaling in Human Colorectal Cancer Cells and Suppresses Tumor Growth in Multiple Intestinal Neoplasia MiceMonensin Inhibits Wnt\/\u03b2-Catenin Signaling. Mol Cancer Ther 13(4):812\u2013822","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"3366_CR113","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.exppara.2010.05.012","volume":"126","author":"R Leitao","year":"2010","unstructured":"Leitao R, Rodriguez A (2010) Inhibition\nof Plasmodium sporozoites infection by targeting the host cell. Exp\nParasitol 126(2):273\u2013277","journal-title":"Exp Parasitol"},{"issue":"20","key":"3366_CR114","doi-asserted-by":"crossref","first-page":"PL309","DOI":"10.1016\/S0024-3205(96)00514-0","volume":"59","author":"J Adovelande","year":"1996","unstructured":"Adovelande J, Schr\u00e9vel J (1996) Carboxylic ionophores in malaria chemotherapy: the effects of monensin and nigericin on Plasmodium falciparum in vitro and Plasmodium vinckei petteri in vivo. LifeSci 59(20):PL309\u2013PL315","journal-title":"Life Sci"},{"key":"3366_CR115","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/950658","author":"C Naujokat","year":"2012","unstructured":"Naujokat C, Steinhart R (2012) Salinomycin as a drug for targeting human cancer stem cells 2012. J Biomed Biotechnol. https:\/\/doi.org\/10.1155\/2012\/950658","journal-title":"J Biomed Biotechnol"},{"issue":"3","key":"3366_CR116","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/med.21870","volume":"42","author":"D Qi","year":"2022","unstructured":"Qi D et al (2022) Salinomycin as a potent anticancer stem cell agent: state of the art and future directions. Med Res Rev 42(3):1037\u20131063","journal-title":"Med Res Rev"},{"issue":"2","key":"3366_CR117","doi-asserted-by":"crossref","first-page":"e0211916","DOI":"10.1371\/journal.pone.0211916","volume":"14","author":"J Klose","year":"2019","unstructured":"Klose J et al (2019) Salinomycin: anti-tumor activity in a pre-clinical colorectal cancer model. PLoSOne 14(2):e0211916","journal-title":"PLoS One"},{"key":"3366_CR118","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ejmech.2014.02.031","volume":"76","author":"M Antoszczak","year":"2014","unstructured":"Antoszczak M et al (2014) Synthesis, cytotoxicity and antibacterial activity of new esters of polyether antibiotic\u2013salinomycin. EurJ Med Chem 76:435\u2013444","journal-title":"EurJ Med Chem"},{"issue":"24","key":"3366_CR119","doi-asserted-by":"crossref","first-page":"e01441","DOI":"10.1128\/JVI.01441-18","volume":"92","author":"Y Jang","year":"2018","unstructured":"Jang Y et al (2018) Salinomycin inhibits influenza virus infection by disrupting endosomal acidification and viral matrix protein 2 function. J Virol 92(24):e01441\u2013e01418","journal-title":"J Virol"},{"issue":"28","key":"3366_CR120","doi-asserted-by":"crossref","first-page":"13773","DOI":"10.1039\/C8NR02442A","volume":"10","author":"M Raza","year":"2018","unstructured":"Raza M et al (2018) Long circulatory liposomal maduramicin inhibits the growth of Plasmodium falciparum blood stages in culture and cures murine models of experimental malaria. Nanoscale 10(28):13773\u201313791","journal-title":"Nanoscale"},{"issue":"3","key":"3366_CR121","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1128\/AAC.01796-15","volume":"60","author":"V Rajendran","year":"2015","unstructured":"Rajendran V et al (2015) Stearylamine liposomal delivery of monensin in combination with free artemisinin eliminates blood stages of Plasmodium falciparum in Culture and P. berghei infection in Murine Malaria. Antimicrob Agents Chemother 60(3):1304\u20131318","journal-title":"Antimicrob Agents Chemother"},{"issue":"23","key":"3366_CR122","doi-asserted-by":"crossref","first-page":"7002","DOI":"10.1016\/j.bmcl.2012.09.046","volume":"22","author":"AJB Huczy\u0144ski","year":"2012","unstructured":"Huczy\u0144ski AJB, Letters MC (2012) Polyether ionophores\u2014promising bioactive molecules for cancer therapy. Bioorg\nMed Chem Lett 22(23):7002\u20137010","journal-title":"Bioorg Med Chem Lett"},{"key":"3366_CR123","doi-asserted-by":"crossref","first-page":"122091","DOI":"10.1016\/j.ijpharm.2022.122091","volume":"625","author":"X Song","year":"2022","unstructured":"Song X et al (2022) Repurposing maduramicin as a novel anticancer and anti-metastasis agent for triple-negative breast cancer as enhanced by nanoemulsion. Int J Pharm 625:122091","journal-title":"Int J Pharm"},{"issue":"3","key":"3366_CR124","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.celrep.2016.12.068","volume":"18","author":"K Rausch","year":"2017","unstructured":"Rausch K et al (2017) Screening bioactives reveals nanchangmycin as a broad spectrum antiviral active against Zika virus. Cell Rep 18(3):804\u2013815","journal-title":"Cell Rep"},{"issue":"2","key":"3366_CR125","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1021\/acsptsci.8b00007","volume":"1","author":"M Huang","year":"2018","unstructured":"Huang M et al (2018) Aglycone polyether nanchangmycin and its homologues exhibit apoptotic and antiproliferative activities against cancer stem cells. ACS Pharmacol Transl Sci 1(2):84\u201395","journal-title":"ACS Pharmacol Transl Sci"},{"key":"3366_CR126","doi-asserted-by":"publisher","DOI":"10.1101\/2022.04.20.440626","author":"JJ Patten","year":"2022","unstructured":"Patten JJ et al (2022) Identification of druggable host targets needed for SARS-CoV-2 infection by combined pharmacological evaluation and cellular network directed prioritization both in vitro and in vivo. J BioRxiv. https:\/\/doi.org\/10.1101\/2022.04.20.440626","journal-title":"J BioRxiv"},{"issue":"7","key":"3366_CR127","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1002\/ptr.7039","volume":"35","author":"SI Ali","year":"2021","unstructured":"Ali SI et al (2021) Medicinal plants: treasure for antiviral drug discovery. Phytother Res 35(7):3447\u20133483","journal-title":"Phytother Res"},{"issue":"4","key":"3366_CR128","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0167-4889(82)90088-X","volume":"721","author":"L Kov\u00e1\u010d","year":"1982","unstructured":"Kov\u00e1\u010d L, B\u00f6hmerov\u00e1 E, Butko P (1982) Ionophores and intact cells\u00a0I. Valinomycin and nigericin act preferentially on mitochondria and not on the plasma membrane of Saccharomyces cerevisiae. Biochim Biophys Acta 721(4):341\u2013348","journal-title":"Biochim Biophys Acta"},{"issue":"7","key":"3366_CR129","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1021\/sb400082j","volume":"3","author":"J Jaitzig","year":"2014","unstructured":"Jaitzig J et al (2014) Reconstituted biosynthesis of the nonribosomal macrolactone antibiotic valinomycin in Escherichia coli. ACS Synth Biol 3(7):432\u2013438","journal-title":"ACS Synth Biol"},{"issue":"3","key":"3366_CR130","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/(SICI)1096-9063(199903)55:3<379::AID-PS919>3.0.CO;2-M","volume":"55","author":"K Fiebich","year":"1999","unstructured":"Fiebich K et al (1999) The insecticidal activity of derivatives of the ionophore X-206. Pestic Sci 55(3):379\u2013381","journal-title":"Pestic Sci"},{"issue":"5","key":"3366_CR131","doi-asserted-by":"crossref","first-page":"e2021579118","DOI":"10.1073\/pnas.2021579118","volume":"118","author":"J-T Jan","year":"2021","unstructured":"Jan J-T et al (2021) Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection. Proc Natl Acad Sci USA 118(5):e2021579118","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Current Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-023-03366-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00284-023-03366-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-023-03366-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T06:09:17Z","timestamp":1689401357000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00284-023-03366-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,6]]},"references-count":131,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["3366"],"URL":"https:\/\/doi.org\/10.1007\/s00284-023-03366-1","relation":{},"ISSN":["0343-8651","1432-0991"],"issn-type":[{"value":"0343-8651","type":"print"},{"value":"1432-0991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,6]]},"assertion":[{"value":"4 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"273"}}